Danaher Corporation (NYSE:DHR) is one of the best strong buy healthcare stocks to buy now. On July 23, UBS lowered the firm’s ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Danaher ( (DHR) ) has issued an update.

In this piece, we will look at the stocks Jim Cramer recently discussed.

Danaher reported generating $1.1 billion in free cash flow during the quarter, with adjusted diluted net earnings per share increasing by approximately 5% year-over-year. This financial strength ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Danaher Corporation thrives on bioprocessing demand and diagnostics resilience. Click for why, with solid execution and 80% ...

Q2 2025 Earnings Call Transcript July 22, 2025 Danaher Corporation beats earnings expectations. Reported EPS is $1.8, expectations were $1.64. Margaux: My name is Margaux, and I’ll be your conference ...

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the ...

Danaher (NYSE:DHR) stock falls even as the company beats Q2 2025 forecasts despite an underperformance at its Life Sciences ...

" Matt McGrew's financial leadership over the past two decades has been instrumental in shaping the Danaher you see today. He played a pivotal role in the acquisition of Cytiva, the launches of ...

The industrial and medical device maker posted revenue of $5.94 billion in the period, which also topped Street forecasts. Eight analysts surveyed by Zacks expected $5.84 billion. Danaher expects full ...

This was the stock's third consecutive day of losses.